These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 30707391)

  • 21. Safety and Efficacy of Long-Term Tocilizumab in a Cohort of Patients with Giant Cell Arteritis: An Italian Monocentric Retrospective Study.
    Terribili R; Grazzini S; Conticini E; Falsetti P; Biasi G; Fabiani C; Cantarini L; Frediani B
    Biologics; 2024; 18():297-305. PubMed ID: 39376549
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial.
    Strand V; Dimonaco S; Tuckwell K; Klearman M; Collinson N; Stone JH
    Arthritis Res Ther; 2019 Feb; 21(1):64. PubMed ID: 30786937
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica.
    Unizony S; Arias-Urdaneta L; Miloslavsky E; Arvikar S; Khosroshahi A; Keroack B; Stone JR; Stone JH
    Arthritis Care Res (Hoboken); 2012 Nov; 64(11):1720-9. PubMed ID: 22674883
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-world Risk of Relapse of Giant Cell Arteritis Treated With Tocilizumab: A Retrospective Analysis of 43 Patients.
    Clément J; Duffau P; Constans J; Schaeverbeke T; Viallard JF; Barcat D; Vernhes JP; Sailler L; Bonnet F
    J Rheumatol; 2021 Sep; 48(9):1435-1441. PubMed ID: 33589561
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Do solar cycles influence giant cell arteritis and rheumatoid arthritis incidence?
    Wing S; Rider LG; Johnson JR; Miller FW; Matteson EL; Crowson CS; Gabriel SE
    BMJ Open; 2015 May; 5(5):e006636. PubMed ID: 25979866
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness Of Tocilizumab In Aortitis And Aneurysms Associated With Giant Cell Arteritis.
    Martín-Gutiérrez A; Loricera J; Narváez J; Aldasoro V; Maiz O; Vela P; Romero-Yuste S; de Miguel E; Galíndez-Agirregoikoa E; Fernández-López JC; Ferraz-Amaro I; Sánchez-Martín J; Moya P; Campos C; López-Gutiérrez F; Castañeda S; Blanco R;
    Eur J Intern Med; 2024 Nov; 129():78-86. PubMed ID: 38908981
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-Term Safety and Efficacy of Subcutaneously Administered Tocilizumab for Adult Rheumatoid Arthritis: A Multicenter Phase 3b Long-term Extension Study.
    Kivitz A; Wallace T; Olech E; Borofsky M; Devenport J; Pei J; Michalska M
    Rheumatol Ther; 2016 Dec; 3(2):291-304. PubMed ID: 27747585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term treatment with tocilizumab in giant cell arteritis: efficacy and safety in a monocentric cohort of patients.
    Regola F; Cerudelli E; Bosio G; Andreoli L; Tincani A; Franceschini F; Toniati P
    Rheumatol Adv Pract; 2020; 4(2):rkaa017. PubMed ID: 32685912
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Effect of Tocilizumab on Inflammatory Markers in Patients Hospitalized with Serious Infections. Case Series and Review of Literature.
    Berman M; Ben-Ami R; Berliner S; Anouk M; Kaufman I; Broyde A; Borok S; Elkayam O
    Life (Basel); 2021 Mar; 11(3):. PubMed ID: 33804790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients.
    Loricera J; Blanco R; Hernández JL; Castañeda S; Mera A; Pérez-Pampín E; Peiró E; Humbría A; Calvo-Alén J; Aurrecoechea E; Narváez J; Sánchez-Andrade A; Vela P; Díez E; Mata C; Lluch P; Moll C; Hernández Í; Calvo-Río V; Ortiz-Sanjuán F; González-Vela C; Pina T; González-Gay MÁ
    Semin Arthritis Rheum; 2015 Jun; 44(6):717-23. PubMed ID: 25697557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Faster steroid-free remission with tocilizumab compared to methotrexate in giant cell arteritis: a real-life experience in two reference centres.
    Quartuccio L; Treppo E; De Martino M; Pillon M; Perniola S; Bruno D; Isola M; Gremese E
    Intern Emerg Med; 2024 Aug; ():. PubMed ID: 39093541
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term efficacy and safety of tocilizumab in giant cell arteritis and large vessel vasculitis.
    Evans J; Steel L; Borg F; Dasgupta B
    RMD Open; 2016; 2(1):e000137. PubMed ID: 26819753
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tocilizumab in Giant Cell Arteritis: A Real-Life Retrospective Study.
    Vitiello G; Orsi Battaglini C; Carli G; Radice A; Matucci A; Vultaggio A; Olianti C; Parronchi P; Maggi E; Cammelli D
    Angiology; 2018 Oct; 69(9):763-769. PubMed ID: 29343075
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tocilizumab in visual involvement of giant cell arteritis: a multicenter study of 471 patients.
    Loricera J; Castañeda S; Moriano C; Narváez J; Aldasoro V; Maiz O; Melero R; Villa I; Vela P; Romero-Yuste S; Callejas JL; de Miguel E; Galíndez-Agirregoikoa E; Sivera F; Fernández-López JC; Galisteo C; Ferraz-Amaro I; Sánchez-Martín J; Sánchez-Bilbao L; Calderón-Goercke M; Casado A; Hernández JL; González-Gay MA; Blanco R
    Ther Adv Musculoskelet Dis; 2022; 14():1759720X221113747. PubMed ID: 35898567
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tocilizumab in giant cell arteritis: an update for the clinician.
    Ford JA; Gewurz D; Gewurz-Singer O
    Curr Opin Rheumatol; 2023 May; 35(3):135-140. PubMed ID: 36912060
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tocilizumab in rheumatoid arthritis: a meta-analysis of efficacy and selected clinical conundrums.
    Navarro G; Taroumian S; Barroso N; Duan L; Furst D
    Semin Arthritis Rheum; 2014 Feb; 43(4):458-69. PubMed ID: 24262929
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A multicentre, large-scale, observational study of tocilizumab in patients with giant cell arteritis in Japan.
    Harigai M; Miyamae T; Hashimoto H; Umetsu K; Yamashita K; Nakaoka Y
    Mod Rheumatol; 2024 Jul; 34(4):775-783. PubMed ID: 37522620
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New-onset cutaneous sarcoidosis under tocilizumab treatment for giant cell arteritis: a quasi-paradoxical adverse drug reaction. Case report and literature review.
    Del Giorno R; Iodice A; Mangas C; Gabutti L
    Ther Adv Musculoskelet Dis; 2019; 11():1759720X19841796. PubMed ID: 31019572
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing.
    Stubenrauch K; Wessels U; Birnboeck H; Ramirez F; Jahreis A; Schleypen J
    Clin Ther; 2010 Aug; 32(9):1597-609. PubMed ID: 20974317
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tocilizumab in Giant Cell Arteritis: A Multicenter Retrospective Study of 34 Patients.
    Régent A; Redeker S; Deroux A; Kieffer P; Ly KH; Dougados M; Liozon E; Larroche C; Guillevin L; Bouillet L; Espitia O; Costedoat-Chalumeau N; Soubrier M; Brihaye B; Lifermann F; Lefevre G; Puéchal X; Mouthon L; Toussirot E;
    J Rheumatol; 2016 Aug; 43(8):1547-52. PubMed ID: 27182063
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.